Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × MDS × Azacitidine × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 38 Myelodysplastic Syndromes 4 Leukemia, Myelomonocytic, Chronic 4 Leukemia 4 Recurrence 2 Pathologic Complete Response 2 Neoplasms 2 MDS 1 Lymphoma, T-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, Myeloid 1 Higher-risk Myelodysplastic Syndrome 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

eprenetapopt 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03745716 2025-03-18

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Aprea Therapeutics

Phase 3 Completed

154 enrolled 10 charts

MDS

Data powered by HemOnc (CC BY 4.0) Colophon ⚡